FDA Inspection 1240356 — ImpactLife
The FDA completed an inspection of ImpactLife on May 30, 2024 in Davenport, IA. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Biologics.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- May 30, 2024
- Fiscal Year
- 2024
- Product Type
- Biologics
- Project Area
- Blood and Blood Products
- Location
- Davenport, IA (United States)